drug
POMALIDOMIDE
Marketedupdated 3mo agoby Celgene Corp
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3all catalysts(5)
approval · 5
Trials studying POMALIDOMIDE
- phase2A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
- phase2AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
- phase1A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
- phase1A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
- phase3Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- phase1A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
- phase2Comparing Lower Versus Standard Doses of Belantamab Mafodotin With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma.
- phase3A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Aug 30, 2026
10 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (24)
- Dec 21, 2031patentUS 8828427*PED
- Dec 21, 2031patentUS 8828427*PED
- Dec 21, 2031patentUS 8828427*PED
- Dec 21, 2031patentUS 8828427*PED
- Jun 21, 2031compositionUS 88284274.8y
- Jun 21, 2031compositionUS 88284274.8y
- Jun 21, 2031compositionUS 88284274.8y
- Jun 21, 2031compositionUS 88284274.8y
- Nov 19, 2030patentUS 10555939*PED4.3y
- Nov 19, 2030patentUS 10555939*PED4.3y
- Nov 19, 2030patentUS 10555939*PED4.3y
- Nov 19, 2030patentUS 10555939*PED4.3y
- Nov 19, 2030patentUS 9993467*PED4.3y
- Nov 19, 2030patentUS 9993467*PED4.3y
- Nov 19, 2030patentUS 9993467*PED4.3y
- Nov 19, 2030patentUS 9993467*PED4.3y
- May 19, 2030formulationUS 105559393.7y
- May 19, 2030formulationUS 105559393.7y
- May 19, 2030formulationUS 105559393.7y
- May 19, 2030formulationUS 105559393.7y
- May 19, 2030formulationUS 99934673.7y
- May 19, 2030formulationUS 99934673.7y
- May 19, 2030formulationUS 99934673.7y
- May 19, 2030formulationUS 99934673.7y
FDA exclusivities (16)
- Nov 14, 2027PEDPediatric (6mo bonus)1.2y
- Nov 14, 2027PEDPediatric (6mo bonus)1.2y
- Nov 14, 2027PEDPediatric (6mo bonus)1.2y
- Nov 14, 2027PEDPediatric (6mo bonus)1.2y
- May 14, 2027ODE-296Orphan Drug (7y)267d
- May 14, 2027ODE-297Orphan Drug (7y)267d
- May 14, 2027ODE-296Orphan Drug (7y)267d
- May 14, 2027ODE-297Orphan Drug (7y)267d
- May 14, 2027ODE-296Orphan Drug (7y)267d
- May 14, 2027ODE-297Orphan Drug (7y)267d
- May 14, 2027ODE-296Orphan Drug (7y)267d
- May 14, 2027ODE-297Orphan Drug (7y)267d
- Aug 30, 2026PCPC10d
- Aug 30, 2026PCPC10d
- Aug 30, 2026PCPC10d
- Aug 30, 2026PCPC10d
News(1)
- Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myelomaNovo is seeking an injunction that would halt allegedly “misleading” obesity drug ads. Elsewhere, the FDA began reviewing a highly anticipated medicine and a veteran investor landed at an AI startup.biopharma_dive · 26d ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that